Takeda’s ax is about to fall again, this time on some over-the-counter and off-patent prescription drugs in Western Europe that could fetch around €1.5 billion. It's the Japanese drugmaker's latest push for cash to pay down its Shire deal debt.
Anvisa determines precautionary interdiction lot of anti-hypertensive Atenolol
EMS Sigma Pharma recalls batch of Venforin